SOLENSIA SOL 7MG/MLX1ML

Solensia® 7 mg/ml – Breakthrough Monthly Injection for Feline Osteoarthritis Pain

Solensia (frunevetmab) is the first and only FDA-approved monoclonal antibody therapy specifically designed for cats to control the pain associated with osteoarthritis (OA). Manufactured by Zoetis, this innovative veterinary medicinal product offers long-lasting relief with a single subcutaneous injection administered once every month by a veterinarian.

What is Solensia?

Solensia is a sterile, ready-to-use solution for injection containing 7 mg/ml of frunevetmab, a felinized monoclonal antibody (mAb). It targets and neutralizes Nerve Growth Factor (NGF), a key protein involved in the transmission of pain signals in cats suffering from osteoarthritis. By blocking NGF, Solensia significantly reduces joint pain, improves mobility, comfort, and overall quality of life.

Key Benefits

• Once-monthly treatment – Convenient long-acting pain control lasting up to 4 weeks
• Proven efficacy – Clinical studies show significant reduction in OA pain; many owners report improved activity and well-being within 2–3 weeks
• Excellent safety profile – Well tolerated even in cats with mild to moderate chronic kidney disease (IRIS stages 1–2)
• Minimal liver and kidney involvement – Eliminated via normal protein degradation pathways, similar to naturally occurring antibodies
• First-in-class therapy – The only monoclonal antibody approved for veterinary use in cats for OA pain

Indications

For the alleviation and control of pain associated with osteoarthritis in cats aged 12 months and older weighing at least 2.5 kg.

How Solensia Works

In osteoarthritis, damaged joints produce elevated levels of Nerve Growth Factor (NGF). NGF amplifies pain signaling to the brain. Frunevetmab specifically binds to NGF, preventing it from activating pain receptors. The result is effective, targeted pain relief without the systemic effects commonly associated with traditional NSAIDs.

Dosage & Administration

Administered by a licensed veterinarian as a subcutaneous injection once a month.

Recommended dose: 1.0 – 2.8 mg/kg bodyweight. For cats over 7 kg, withdraw the full contents of the required vials into a single syringe and administer as one injection. Use immediately after puncturing the vial (no preservative).

Composition

Each 1 ml vial contains:

• Active substance: Frunevetmab 7 mg (felinized monoclonal antibody expressed in Chinese hamster ovary cells)
• Excipients: L-histidine monohydrochloride, D-sorbitol, polysorbate 20, water for injections, hydrochloric acid / sodium hydroxide (for pH adjustment)

Storage

Store upright in a refrigerator between 2°C – 8°C. Do not freeze. Protect from light. Use immediately after first opening. Shelf life of unopened product: 2 years.

Important Safety Information

• Do not use in cats under 12 months of age or weighing less than 2.5 kg
• Do not use in breeding, pregnant or lactating cats
• Do not use in cases of known hypersensitivity to frunevetmab or any excipient
• Common side effects (1–10% of treated cats): alopecia, dermatitis, pruritus
• Rare: mild injection site reactions, skin scabs or sores
• Very rare: anaphylaxis
• Pregnant women, women trying to conceive and breastfeeding women should take extreme care to avoid accidental self-injection

Why Choose Solensia?

Osteoarthritis is extremely common in cats yet often underdiagnosed. Traditional pain medications can be challenging due to administration difficulties or concerns about long-term use. Solensia provides a modern, targeted, once-monthly solution that helps cats move more comfortably and enjoy a better quality of life — all under veterinary supervision.

Prescription only (POM-V). Always consult your veterinarian for diagnosis and treatment of feline osteoarthritis.